Methylation-Mediated Silencing of SOCS-1 Gene in Hepatocellular Carcinoma Derived from Cirrhosis

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5295-5298

  Okochi, Osamu ^a   Hibi, Kenji ^a   Sakai, Mitsuru ^a   Inoue, Soichiro ^a   Takeda, Shin ^a   Kaneko, Tetsuya ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; MESSENGER RNA; STAT PROTEIN;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CPG ISLAND; FEMALE; GENE; GENE SILENCING; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MALIGNANT TRANSFORMATION; METHYLATION; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SOCS 1 GENE; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

BLOTTING, NORTHERN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; REPRESSOR PROTEINS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 0242610382     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. El-Serag, H. B., and Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med., 340: 745-750, 1999.
2. Taylor-Robinson, S. D., Foster, G. R., Arora, S., Hargreaves, S., and Thomas, H. C. Increase in primary liver cancer in the UK, 1979-94. Lancet, 350: 1142-1143, 1997.
3. Tabor, E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J. Med. Vir., 42: 357-365, 1994.
4. Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., and Ikenaga, M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res., 54: 3107-3110, 1994.
5. de la Costa, A., Romagnolo, B., Billuart, P., Renard, C. A., Buendia, M. A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., and Perret, C. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 95: 8847-8851, 1998.
6. Emi, M., Fujiwara, Y., Ohata, H., Tsuda, H., Hirohashi, S., Koike, M., Miyaki, M., Monden, M., and Nakamura, Y. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer, 7: 152-157, 1993.
7. Yoshikawa, H., Matsubara, K., Qian, G. S., Jackson, P., Groopman, J. D., Manning, J. E., Harris, C. C., and Herman, J. G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet., 28: 29-35, 2001.
8. Cressman, D. E., Diamond, R. H., and Taub, R. Rapid activation of the Stat3 transcription complex in liver regeneration. Hepatology, 21: 1443-1449, 1995.
9. Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., and Taub, R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science (Wash. DC), 274: 1379-1383, 1996.
10. Lacronique, V., Boureux, A., Valle, V. D., Poirel, H., Quang, C. T., Mauchauffe, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., and Bernard, O. A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (Wash. DC), 278: 1309-1312, 1997.
11. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. Stat3 as an oncogene. Cell, 98: 295-303, 1999.
12. Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K., Sata, M., Kohara, M., and Yoshimura, A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med., 196: 641-653, 2002.
13. Hibi, K., Taguchi, M., Nakayama, H., Takase, T., Kasai, Y., Ito, K., Akiyama, S., and Nakao, A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 7: 3135-3138, 2001.
14. Frommer, M., McDonald, L. E., Miller, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., and Paul, C. L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA. 89: 1827-1831, 1992.
15. Hibi, K., Nakamura, H., Hirai, A., Fujikake, Y., Kasai, Y., Akiyama, S., Ito, K., and Takagi, H. Loss of H19 imprinting in esophageal cancer. Cancer Res., 56: 480-482, 1996.
16. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Wash. DC), 264: 1415-1421. 1994.
17. Migone, T. S., Lin, J. X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., and Leonard, W. J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I 1. Science (Wash. DC), 269: 79-81, 1995.
18. Danial, N. N., Pernis, A., and Rothman, P. B. Jak-STAT signaling induced by the v-abl oncogene. Science (Wash. DC), 269: 1875-1877, 1995.
19. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., and Hilton, D. J. A family of cytokine-inducible inhibitors of signaling. Science (Wash. DC), 387: 917-921, 1997.
20. Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., Miyazaki, T., Leonor, N., Taniguchi, T., Fujita, T., Kanakura, Y., Komiya, S., and Yoshimura, A. A new protein containing an SH2 domain that inhibits JAK kinases. Science (Wash. DC), 387: 921-924, 1997.
21. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., Akira, S., and Kishimoto. T. Structure and function of a new STAT-induced STAT inhibitor. Science (Wash. DC), 387: 924-929, 1997.
22. Nagai, H., Kim, Y. S., Lee, K. T., Chu, M. Y., Konishi, N., Fujimoto, J., Baba, M., Matsubara, K., and Emi, M. Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis. J. Hepatol., 34: 416-421, 2001.
23. Jegalian, A. G., and Wu, H. Regulation of Socs gene expression by the proto-oncoprotein GFI-1B: two routes for STAT5 target gene induction by erythropoietin. J. Biol. Chem., 277: 2345-2352, 2002.
24. Andus, T., Bauer, J., and Gerok, W. Effects of cytokines on the liver. Hepatology, 13: 364-375, 1991.
25. Tilg, H., Wilmer, A., Vogel, W., Herold, M., Nolchen, B., Judmaier, G., and Huber, C. Serum levels of cytokines in cirrhotic liver diseases. Gastroenterology, 103: 264-274, 1992.
26. Lee, F. Y., Lu, R. H., Tsai, Y. T., Lin, H. C., Hou, M. C., Li, C. P., Liao, T. M., Lin, L. F., Wang, S. S., and Lee, S. D. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-α, and hyperdynamic circulation. Scand. J. Gastroenterol., 31: 500-505, 1996.
27. Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., and Kawashima, T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med., 328: 1797-1801, 1993.
28. Yeh, S. H., Chen, P. J., Shau, W. Y., Chen, Y. W., Lee, P. H., Chen, J. T., and Chen, D. S. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology, 121: 699-709, 2001.